Drug Profile
Lanabecestat - AstraZeneca
Alternative Names: AZD3293; LY 3314814Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Astex Pharmaceuticals; AstraZeneca
- Developer AstraZeneca; Eli Lilly and Company
- Class Antidementias; Imidazoles; Pyridines; Small molecules; Spiro compounds
- Mechanism of Action BACE1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Alzheimer's disease
Most Recent Events
- 28 Feb 2021 No recent reports of development identified for phase-I development in Alzheimer's-disease(In volunteers) in United Kingdom (IV, Infusion)
- 14 Jul 2019 Efficacy data from the phase II/III AMARANTH trial presented at the Alzheimer's Association International Conference 2019 (AAIC-2019)
- 22 Jul 2018 Pharmacokinetics and adverse events data from a phase I trial (In volunteers) presented at the Alzheimer's Association International Conference (AAIC-2018)